Literature DB >> 23528733

HIV-1 Vpu affects the anterograde transport and the glycosylation pattern of NTB-A.

Sebastian Bolduan1, Philipp Hubel, Tatjana Reif, Veronika Lodermeyer, Kristin Höhne, Joëlle V Fritz, Daniel Sauter, Frank Kirchhoff, Oliver T Fackler, Michael Schindler, Ulrich Schubert.   

Abstract

HIV-1 Vpu induces downregulation of cell surface NTB-A to evade lysis of HIV-1 infected cells by NK cells. Here we show that Vpu affects the anterograde transport and the glycosylation pattern of NTB-A by a mechanism that is distinct from the Vpu induced downregulation of CD4 and tetherin. In the presence of Vpu, only the high mannose form of NTB-A was detectable, suggesting that Vpu prevented the formation of the mature form of NTB-A. This phenomenon is associated with the ability of Vpu to downregulate cell surface NTB-A by retention of NTB-A within the Golgi-compartment. Furthermore, the Vpu-mediated effect on NTB-A glycosylation is highly conserved among Vpu proteins derived from HIV-1 and SIV and corresponds to the level of downregulation of NTB-A. Together, these results suggest that the reduction of NTB-A from the cell surface is associated with the Vpu-mediated effect on the glycosylation pattern of newly synthesized NTB-A molecules.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23528733      PMCID: PMC3644704          DOI: 10.1016/j.virol.2013.02.021

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  58 in total

1.  The palmitoylation machinery is a spatially organizing system for peripheral membrane proteins.

Authors:  Oliver Rocks; Marc Gerauer; Nachiket Vartak; Sebastian Koch; Zhi-Ping Huang; Markos Pechlivanis; Jürgen Kuhlmann; Lucas Brunsveld; Anchal Chandra; Bernhard Ellinger; Herbert Waldmann; Philippe I H Bastiaens
Journal:  Cell       Date:  2010-04-22       Impact factor: 41.582

2.  Antagonism of CD317 restriction of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 Vpu.

Authors:  Christine Goffinet; Stefanie Homann; Ina Ambiel; Nadine Tibroni; Daniel Rupp; Oliver T Keppler; Oliver T Fackler
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

3.  Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.

Authors:  Janet L Douglas; Kasinath Viswanathan; Matthew N McCarroll; Jean K Gustin; Klaus Früh; Ashlee V Moses
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

4.  HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes.

Authors:  Yukie Iwabu; Hideaki Fujita; Masanobu Kinomoto; Keiko Kaneko; Yukihito Ishizaka; Yoshitaka Tanaka; Tetsutaro Sata; Kenzo Tokunaga
Journal:  J Biol Chem       Date:  2009-10-16       Impact factor: 5.157

5.  A flow cytometry-based FRET assay to identify and analyse protein-protein interactions in living cells.

Authors:  Carina Banning; Jörg Votteler; Dirk Hoffmann; Herwig Koppensteiner; Martin Warmer; Rudolph Reimer; Frank Kirchhoff; Ulrich Schubert; Joachim Hauber; Michael Schindler
Journal:  PLoS One       Date:  2010-02-22       Impact factor: 3.240

6.  Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment.

Authors:  Mathieu Dubé; Bibhuti Bhusan Roy; Pierre Guiot-Guillain; Julie Binette; Johanne Mercier; Antoine Chiasson; Eric A Cohen
Journal:  PLoS Pathog       Date:  2010-04-08       Impact factor: 6.823

7.  Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains.

Authors:  Daniel Sauter; Michael Schindler; Anke Specht; Wilmina N Landford; Jan Münch; Kyeong-Ae Kim; Jörg Votteler; Ulrich Schubert; Frederic Bibollet-Ruche; Brandon F Keele; Jun Takehisa; Yudelca Ogando; Christina Ochsenbauer; John C Kappes; Ahidjo Ayouba; Martine Peeters; Gerald H Learn; George Shaw; Paul M Sharp; Paul Bieniasz; Beatrice H Hahn; Theodora Hatziioannou; Frank Kirchhoff
Journal:  Cell Host Microbe       Date:  2009-11-19       Impact factor: 21.023

8.  Vpu serine 52 dependent counteraction of tetherin is required for HIV-1 replication in macrophages, but not in ex vivo human lymphoid tissue.

Authors:  Michael Schindler; Devi Rajan; Carina Banning; Peter Wimmer; Herwig Koppensteiner; Alicja Iwanski; Anke Specht; Daniel Sauter; Thomas Dobner; Frank Kirchhoff
Journal:  Retrovirology       Date:  2010-01-15       Impact factor: 4.602

9.  HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation.

Authors:  Bastien Mangeat; Gustavo Gers-Huber; Martin Lehmann; Madeleine Zufferey; Jeremy Luban; Vincent Piguet
Journal:  PLoS Pathog       Date:  2009-09-04       Impact factor: 6.823

10.  Tetherin inhibits HIV-1 release by directly tethering virions to cells.

Authors:  David Perez-Caballero; Trinity Zang; Alaleh Ebrahimi; Matthew W McNatt; Devon A Gregory; Marc C Johnson; Paul D Bieniasz
Journal:  Cell       Date:  2009-10-30       Impact factor: 41.582

View more
  21 in total

1.  HIV-1 Vpu Downmodulates ICAM-1 Expression, Resulting in Decreased Killing of Infected CD4+ T Cells by NK Cells.

Authors:  Scott M Sugden; Tram N Q Pham; Éric A Cohen
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

2.  HIV-1 Vpu mediated downregulation of CD155 requires alanine residues 10, 14 and 18 of the transmembrane domain.

Authors:  Sebastian Bolduan; Tatjana Reif; Michael Schindler; Ulrich Schubert
Journal:  Virology       Date:  2014-08-09       Impact factor: 3.616

Review 3.  Various plus unique: Viral protein U as a plurifunctional protein for HIV-1 replication.

Authors:  Andrew Soper; Guillermo Juarez-Fernandez; Hirofumi Aso; Miyu Moriwaki; Eri Yamada; Yusuke Nakano; Yoshio Koyanagi; Kei Sato
Journal:  Exp Biol Med (Maywood)       Date:  2017-01-01

4.  HIV-1 Nef and Vpu are functionally redundant broad-spectrum modulators of cell surface receptors, including tetraspanins.

Authors:  Claudia Haller; Birthe Müller; Joëlle V Fritz; Miguel Lamas-Murua; Bettina Stolp; François M Pujol; Oliver T Keppler; Oliver T Fackler
Journal:  J Virol       Date:  2014-10-01       Impact factor: 5.103

5.  HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly Sites.

Authors:  François M Pujol; Vibor Laketa; Florian Schmidt; Markus Mukenhirn; Barbara Müller; Steeve Boulant; Dirk Grimm; Oliver T Keppler; Oliver T Fackler
Journal:  J Virol       Date:  2016-07-11       Impact factor: 5.103

6.  Detection of the HIV-1 Accessory Proteins Nef and Vpu by Flow Cytometry Represents a New Tool to Study Their Functional Interplay within a Single Infected CD4+ T Cell.

Authors:  Jérémie Prévost; Jonathan Richard; Romain Gasser; Halima Medjahed; Frank Kirchhoff; Beatrice H Hahn; John C Kappes; Christina Ochsenbauer; Ralf Duerr; Andrés Finzi
Journal:  J Virol       Date:  2022-01-26       Impact factor: 6.549

Review 7.  Innate antiviral immune signaling, viral evasion and modulation by HIV-1.

Authors:  Arjun Rustagi; Michael Gale
Journal:  J Mol Biol       Date:  2013-12-08       Impact factor: 5.469

8.  Structural basis of HIV-1 Vpu-mediated BST2 antagonism via hijacking of the clathrin adaptor protein complex 1.

Authors:  Xiaofei Jia; Erin Weber; Andrey Tokarev; Mary Lewinski; Maryan Rizk; Marissa Suarez; John Guatelli; Yong Xiong
Journal:  Elife       Date:  2014-04-29       Impact factor: 8.140

9.  HIV-1 Vpu utilizes both cullin-RING ligase (CRL) dependent and independent mechanisms to downmodulate host proteins.

Authors:  Peter W Ramirez; Ana Beatriz DePaula-Silva; Matt Szaniawski; Edward Barker; Alberto Bosque; Vicente Planelles
Journal:  Retrovirology       Date:  2015-07-28       Impact factor: 4.602

10.  HIV-1 Vpu Downregulates Tim-3 from the Surface of Infected CD4+ T Cells.

Authors:  Jérémie Prévost; Cassandra R Edgar; Jonathan Richard; Steven M Trothen; Rajesh Abraham Jacob; Mitchell J Mumby; Suzanne Pickering; Mathieu Dubé; Daniel E Kaufmann; Frank Kirchhoff; Stuart J D Neil; Andrés Finzi; Jimmy D Dikeakos
Journal:  J Virol       Date:  2020-03-17       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.